Filtered By:
Source: Stroke
Nutrition: Vitamins

This page shows you your search results in order of date.

Order by Relevance | Date

Total 37 results found since Jan 2013.

Factor Xa Inhibitors Versus Vitamin K Antagonists for Prevention of Cerebral or Systemic Embolism in Patients With Atrial Fibrillation Cochrane Corner
Source: Stroke - June 25, 2018 Category: Neurology Authors: Karsten M.H. Bruins Slot, Eivind Berge Tags: Atrial Fibrillation, Anticoagulants, Cerebrovascular Disease/Stroke Cochrane Corner Source Type: research

Continuation or Discontinuation of Anticoagulation in the Early Phase After Acute Ischemic Stroke Brief Report
Background and Purpose—There is no consensus on whether anticoagulation should be continued or temporarily stopped in patients suffering acute ischemic stroke while using anticoagulation. We assessed treatment variations and outcomes in these patients.Methods—Post hoc analysis of PASS (Preventive Antibiotics in Stroke Study). We included patients with acute ischemic stroke who used anticoagulation at admission. We compared clinical outcomes, thrombotic, and major bleeding events at 3 months.Results—Nine percent (192/2101) of the patients with acute ischemic stroke used anticoagulation at admission (186 vitamin K anta...
Source: Stroke - June 25, 2018 Category: Neurology Authors: Adrien E. Groot, Jan-Dirk M. Vermeij, Willeke F. Westendorp, Paul J. Nederkoorn, Diederik van de Beek, Jonathan M. Coutinho Tags: Secondary Prevention, Anticoagulants, Cerebrovascular Disease/Stroke, Ischemic Stroke Brief Reports Source Type: research

Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation Clinical Sciences
Conclusions—Upfront procedure costs initially make LAAC higher cost than warfarin and the non–vitamin K antagonist oral anticoagulants, but within 10 years, LAAC delivers more quality-adjusted life years and has lower total costs, making LAAC the most cost-effective treatment strategy for secondary prevention of stroke in atrial fibrillation.
Source: Stroke - May 25, 2018 Category: Neurology Authors: Vivek Y. Reddy, Ronald L. Akehurst, Stacey L. Amorosi, Meghan B. Gavaghan, Deanna S. Hertz, David R. Holmes Jr Tags: Atrial Fibrillation, Cost-Effectiveness Original Contributions Source Type: research

Relationship Between Dietary Vitamin D and Deaths From Stroke and Coronary Heart Disease Brief Report
Background and Purpose—There is growing evidence about the importance of vitamin D for cardiovascular health. Therefore, we examined the relationship between dietary vitamin D intake and risk of mortality from stroke and coronary heart disease in Japanese population.Methods—A prospective study encompassing 58 646 healthy Japanese adults (23 099 men and 35 547 women) aged of 40 to 79 years in whom dietary vitamin D intake was determined via a self-administered food frequency questionnaire. The median follow-up period was 19.3 years (1989–2009). The hazard ratios and 95% confidence intervals of mortality were calcu...
Source: Stroke - January 22, 2018 Category: Neurology Authors: Haytham A. Sheerah, Ehab S. Eshak, Renzhe Cui, Hironori Imano, Hiroyasu Iso, Akiko Tamakoshi Tags: Cardiovascular Disease, Diet and Nutrition, Epidemiology, Risk Factors, Cerebrovascular Disease/Stroke Brief Reports Source Type: research

Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack Clinical Sciences
Conclusions—These results suggest that exposure to SVA, an inhibitor of HDAC, may be associated with a lower recurrent stroke risk although we cannot exclude residual confounding in this study design. This supports the hypothesis that HDAC9 is important in the ischemic stroke pathogenesis and that its inhibition, by SVA or a more specific HDAC9 inhibitor, is worthy of evaluation as a treatment to prevent recurrent ischemic stroke.
Source: Stroke - December 22, 2017 Category: Neurology Authors: Rebecca L. Brookes, Siobhan Crichton, Charles D.A. Wolfe, Qilong Yi, Linxin Li, Graeme J. Hankey, Peter M. Rothwell, Hugh S. Markus Tags: Secondary Prevention, Genetics, Ischemic Stroke, Atherosclerosis Original Contributions Source Type: research

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation Clinical Sciences
Conclusions—In real-world practice among a high-risk Asian atrial fibrillation population, all 3 NOACs demonstrated similar risk of ischemic stroke and lower risk of ICH compared with warfarin. All-cause mortality was significantly lower only with dabigatran and apixaban.
Source: Stroke - October 23, 2017 Category: Neurology Authors: Myung-Jin Cha, Eue-Keun Choi, Kyung-Do Han, So-Ryoung Lee, Woo-Hyun Lim, Seil Oh, Gregory Y.H. Lip Tags: Atrial Fibrillation Original Contributions Source Type: research

Fibrin Clot Permeability as a Predictor of Stroke and Bleeding in Anticoagulated Patients With Atrial Fibrillation Clinical Sciences
Background and Purpose—Formation of denser fiber networks has been reported in atrial fibrillation and ischemic stroke. In this longitudinal cohort study, we evaluated whether fibrin clot density may predict thromboembolic and bleeding risk in patients with atrial fibrillation on vitamin K antagonists.Methods—In 236 patients with atrial fibrillation receiving vitamin K antagonists treatment, we measured ex vivo plasma clot permeability (Ks), a measure of the pore size in fibrin networks.Results—During a median follow-up of 4.3 (interquartile range, 3.7–4.8) years, annual rates of ischemic stroke or transient ischem...
Source: Stroke - September 25, 2017 Category: Neurology Authors: Leszek Drabik, Paweł Wołkow, Anetta Undas Tags: Atrial Fibrillation, Ischemic Stroke, Thrombosis Original Contributions Source Type: research

Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation Clinical Sciences
Conclusions—This meta-analysis confirms the main findings of the randomized controlled trials of dabigatran, rivaroxaban, and apixaban in the real-world setting and, hence, strengthens their validity.
Source: Stroke - August 28, 2017 Category: Neurology Authors: George Ntaios, Vasileios Papavasileiou, Konstantinos Makaritsis, Konstantinos Vemmos, Patrik Michel, Gregory Y.H. Lip Tags: Arrhythmias, Secondary Prevention, Meta Analysis, Mortality/Survival, Ischemic Stroke Original Contributions Source Type: research

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack Clinical Sciences
Conclusions—Results from our study of the 3 NOACs versus warfarin in nonvalvular atrial fibrillation patients with a previous history of stroke/transient ischemic attack are relatively consistent with their respective phase III trials and previous stroke/transient ischemic attack subgroup analyses. All NOACs seemed no worse than warfarin in respect to ischemic stroke, ICH, or major bleeding risk.
Source: Stroke - July 24, 2017 Category: Neurology Authors: Craig I. Coleman, W. Frank Peacock, Thomas J. Bunz, Mark J. Alberts Tags: Arrhythmias, Quality and Outcomes, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research

Intravenous Thrombolysis in Acute Ischemic Stroke Patients Pretreated With Non-Vitamin K Antagonist Oral Anticoagulants Emerging Therapy Critique
Source: Stroke - June 26, 2017 Category: Neurology Authors: Georgios Tsivgoulis, Apostolos Safouris Tags: Ischemic Stroke Emerging Therapy Critiques Source Type: research

Genetic Drivers of von Willebrand Factor Levels in an Ischemic Stroke Population and Association With Risk for Recurrent Stroke Clinical Sciences
Background and Purpose—von Willebrand factor (vWF) plays an important role in thrombus formation during cerebrovascular damage. We sought to investigate the potential role of circulating vWF in recurrent cerebrovascular events and identify genetic contributors to variation in vWF level in an ischemic stroke population.Methods—We analyzed the effect of circulating vWF on risk of recurrent stroke using survival models in the VISP trial (Vitamin Intervention for Stroke Prevention) and the use of vWF in reclassification over traditional factors. We conducted a genome-wide association study) with imputation, based on 1000 G...
Source: Stroke - May 22, 2017 Category: Neurology Authors: Stephen R. Williams, Fang–Chi Hsu, Keith L. Keene, Wei–Min Chen, Godfrey Dzhivhuho, Joe L. Rowles III, Andrew M. Southerland, Karen L. Furie, Stephen S. Rich, Bradford B. Worrall, Michele M. Sale Tags: Biomarkers, Cerebrovascular Disease/Stroke, Ischemic Stroke Original Contributions Source Type: research

Restarting Anticoagulant Therapy After Intracranial Hemorrhage Clinical Sciences
Background and Purpose—The safety and efficacy of restarting anticoagulation therapy after intracranial hemorrhage (ICH) remain unclear. We performed a systematic review and meta-analysis to summarize the associations of anticoagulation resumption with the subsequent risk of ICH recurrence and thromboembolism.Methods—We searched published medical literature to identify cohort studies involving adults with anticoagulation-associated ICH. Our predictor variable was resumption of anticoagulation. Outcome measures were thromboembolic events (stroke and myocardial infarction) and recurrence of ICH. After assessing study het...
Source: Stroke - May 22, 2017 Category: Neurology Authors: Santosh B. Murthy, Ajay Gupta, Alexander E. Merkler, Babak B. Navi, Pitchaiah Mandava, Costantino Iadecola, Kevin N. Sheth, Daniel F. Hanley, Wendy C. Ziai, Hooman Kamel Tags: Catheter Ablation and Implantable Cardioverter-Defibrillator, Myocardial Infarction, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research

Is There an Obesity Paradox for Outcomes in Atrial Fibrillation? Clinical Sciences
Conclusions—There may be an obesity paradox in atrial fibrillation patients, particularly for all-cause and cardiovascular death outcomes. An obesity paradox was also evident for stroke/systemic embolic event outcome in NOAC trials, with a treatment effect favoring NOACs over warfarin for both efficacy and safety that was significant only for normal weight patients.
Source: Stroke - March 27, 2017 Category: Neurology Authors: Marco Proietti, Elisa Guiducci, Paola Cheli, Gregory Y.H. Lip Tags: Catheter Ablation and Implantable Cardioverter-Defibrillator, Obesity, Anticoagulants, Quality and Outcomes Original Contributions Source Type: research

Safety of Endovascular Thrombectomy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants Brief Reports
Conclusions— Thrombectomy in non–vitamin K antagonist oral anticoagulant patients seems safe although a comparatively high rate of asymptomatic hemorrhagic transformation was noted. Confirmation in larger prospective controlled cohorts is necessary. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01850797.
Source: Stroke - March 27, 2016 Category: Neurology Authors: Purrucker, J. C., Wolf, M., Haas, K., Rizos, T., Khan, S., Dziewas, R., Kleinschnitz, C., Binder, A., Groschel, K., Hennerici, M. G., Lobotesis, K., Poli, S., Seidel, G., Neumann-Haefelin, T., Ringleb, P. A., Heuschmann, P. U., Veltkamp, R. Tags: Angiography, Anticoagulants, Ischemic Stroke Brief Reports Source Type: research

Endovascular Treatment for Acute Ischemic Stroke in the Setting of Anticoagulation Brief Reports
Conclusions— Intra-arterial therapy seems to be safe in patients taking OACs; however, our study showed a nonsignificant increase in hemorrhage and mortality with a nonsignificant decrease in good outcomes in comparison with non-OAC patients. Although these nominal differences may have been related to older age and more comorbidities in the OAC group, larger studies are needed to confirm our findings given our limited sample size.
Source: Stroke - November 23, 2015 Category: Neurology Authors: Rebello, L. C., Haussen, D. C., Belagaje, S., Anderson, A., Frankel, M., Nogueira, R. G. Tags: Anticoagulants, Cerebrovascular Disease/Stroke, Ischemic Stroke Brief Reports Source Type: research